ICAM1 and glioblastoma: This can be explained by greater heterogeneity in HLA-C1/C2 licensing within these subsets among the donors, hence their greater heterogeneity in LFA-1 expression and intermediate/moderate cytotoxicity against ICAM-1 expressing GBM targets.